Direct PCR: A new pharmacogenetic approach for the inexpensive testing of HLA-B∗57:01

R. Cascella, C. Strafella, M. Ragazzo, S. Zampatti, P. Borgiani, S. Gambardella, A. Pirazzoli, G. Novelli, E. Giardina

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

One of the most successful applications of pharmacogenetics research is the genetic screening for HLA-B∗57:01, strongly associated with an increased risk to develop hypersensitivity reaction in HIV-positive patients following abacavir administration. Taking into consideration the limits of current genotyping methodologies, we have developed and validated (150 buccal swabs) an inexpensive pharmacogenetic approach for HLA-B∗57:01 typing. In our assay DNA extraction and amplification are combined in one single step (direct PCR protocol), which is performed directly on the biological sample without the need of extraction and sequencing passages. The amplicons obtained by direct PCR can be easily separated on the agarose gel under ultraviolet. As per our results, the direct PCR represents a good alternative to the traditional methods of HLA-B∗57:01 pharmacogenetic test, especially for those laboratories or countries where currently available approaches are often not available or not affordable. Furthermore it is an innovative approach, promoting a personalized, safer and cost-effective therapy.

Original languageEnglish
Pages (from-to)196-200
Number of pages5
JournalPharmacogenomics Journal
Volume15
Issue number2
DOIs
Publication statusPublished - Apr 25 2015

Fingerprint

Pharmacogenetics
Polymerase Chain Reaction
Cheek
Genetic Testing
Sepharose
Hypersensitivity
Gels
HIV
Costs and Cost Analysis
DNA
Research
HLA-B57 antigen
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine
  • Genetics

Cite this

Direct PCR : A new pharmacogenetic approach for the inexpensive testing of HLA-B∗57:01. / Cascella, R.; Strafella, C.; Ragazzo, M.; Zampatti, S.; Borgiani, P.; Gambardella, S.; Pirazzoli, A.; Novelli, G.; Giardina, E.

In: Pharmacogenomics Journal, Vol. 15, No. 2, 25.04.2015, p. 196-200.

Research output: Contribution to journalArticle

Cascella, R, Strafella, C, Ragazzo, M, Zampatti, S, Borgiani, P, Gambardella, S, Pirazzoli, A, Novelli, G & Giardina, E 2015, 'Direct PCR: A new pharmacogenetic approach for the inexpensive testing of HLA-B∗57:01', Pharmacogenomics Journal, vol. 15, no. 2, pp. 196-200. https://doi.org/10.1038/tpj.2014.48
Cascella, R. ; Strafella, C. ; Ragazzo, M. ; Zampatti, S. ; Borgiani, P. ; Gambardella, S. ; Pirazzoli, A. ; Novelli, G. ; Giardina, E. / Direct PCR : A new pharmacogenetic approach for the inexpensive testing of HLA-B∗57:01. In: Pharmacogenomics Journal. 2015 ; Vol. 15, No. 2. pp. 196-200.
@article{e1c8408bffff437982fb3605e8c06b87,
title = "Direct PCR: A new pharmacogenetic approach for the inexpensive testing of HLA-B∗57:01",
abstract = "One of the most successful applications of pharmacogenetics research is the genetic screening for HLA-B∗57:01, strongly associated with an increased risk to develop hypersensitivity reaction in HIV-positive patients following abacavir administration. Taking into consideration the limits of current genotyping methodologies, we have developed and validated (150 buccal swabs) an inexpensive pharmacogenetic approach for HLA-B∗57:01 typing. In our assay DNA extraction and amplification are combined in one single step (direct PCR protocol), which is performed directly on the biological sample without the need of extraction and sequencing passages. The amplicons obtained by direct PCR can be easily separated on the agarose gel under ultraviolet. As per our results, the direct PCR represents a good alternative to the traditional methods of HLA-B∗57:01 pharmacogenetic test, especially for those laboratories or countries where currently available approaches are often not available or not affordable. Furthermore it is an innovative approach, promoting a personalized, safer and cost-effective therapy.",
author = "R. Cascella and C. Strafella and M. Ragazzo and S. Zampatti and P. Borgiani and S. Gambardella and A. Pirazzoli and G. Novelli and E. Giardina",
year = "2015",
month = "4",
day = "25",
doi = "10.1038/tpj.2014.48",
language = "English",
volume = "15",
pages = "196--200",
journal = "Pharmacogenomics Journal",
issn = "1470-269X",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Direct PCR

T2 - A new pharmacogenetic approach for the inexpensive testing of HLA-B∗57:01

AU - Cascella, R.

AU - Strafella, C.

AU - Ragazzo, M.

AU - Zampatti, S.

AU - Borgiani, P.

AU - Gambardella, S.

AU - Pirazzoli, A.

AU - Novelli, G.

AU - Giardina, E.

PY - 2015/4/25

Y1 - 2015/4/25

N2 - One of the most successful applications of pharmacogenetics research is the genetic screening for HLA-B∗57:01, strongly associated with an increased risk to develop hypersensitivity reaction in HIV-positive patients following abacavir administration. Taking into consideration the limits of current genotyping methodologies, we have developed and validated (150 buccal swabs) an inexpensive pharmacogenetic approach for HLA-B∗57:01 typing. In our assay DNA extraction and amplification are combined in one single step (direct PCR protocol), which is performed directly on the biological sample without the need of extraction and sequencing passages. The amplicons obtained by direct PCR can be easily separated on the agarose gel under ultraviolet. As per our results, the direct PCR represents a good alternative to the traditional methods of HLA-B∗57:01 pharmacogenetic test, especially for those laboratories or countries where currently available approaches are often not available or not affordable. Furthermore it is an innovative approach, promoting a personalized, safer and cost-effective therapy.

AB - One of the most successful applications of pharmacogenetics research is the genetic screening for HLA-B∗57:01, strongly associated with an increased risk to develop hypersensitivity reaction in HIV-positive patients following abacavir administration. Taking into consideration the limits of current genotyping methodologies, we have developed and validated (150 buccal swabs) an inexpensive pharmacogenetic approach for HLA-B∗57:01 typing. In our assay DNA extraction and amplification are combined in one single step (direct PCR protocol), which is performed directly on the biological sample without the need of extraction and sequencing passages. The amplicons obtained by direct PCR can be easily separated on the agarose gel under ultraviolet. As per our results, the direct PCR represents a good alternative to the traditional methods of HLA-B∗57:01 pharmacogenetic test, especially for those laboratories or countries where currently available approaches are often not available or not affordable. Furthermore it is an innovative approach, promoting a personalized, safer and cost-effective therapy.

UR - http://www.scopus.com/inward/record.url?scp=84925628792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925628792&partnerID=8YFLogxK

U2 - 10.1038/tpj.2014.48

DO - 10.1038/tpj.2014.48

M3 - Article

C2 - 25201286

AN - SCOPUS:84925628792

VL - 15

SP - 196

EP - 200

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

SN - 1470-269X

IS - 2

ER -